Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).

Trial Details

NCT ID

NCT06639724

Phase

PHASE1

Sponsor

University of California, San Diego

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

Locations (sample)

La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

Patient has the ability to understand and willingness to sign a written informed consent.
Patient is ≥ 18 years of age.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Patient must have surgical consult to verify patient is a surgical candidate within 28 days prior to enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →